← Eichor
Condition: Narcolepsy Type 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Narcolepsy Type 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
Phase 2 · 18 location(s) · Takeda · NCT07633301A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central
Phase 2/Phase 3 · 7 location(s) · Centessa Pharmaceuticals (UK) Limited · NCT07598708A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2 · 24 location(s) · Centessa Pharmaceuticals (UK) Limited · NCT07096674Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcol
NA · 2 location(s) · Hospices Civils de Lyon · NCT06484348Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia
NA · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT05773872Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder
NA · 1 location(s) · University Hospital, Toulouse · NCT07365566A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Phase 2 · 57 location(s) · Eisai Inc. · NCT07493265A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Phase 3 · 22 location(s) · Alkermes, Inc. · NCT07455383A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Phase 2/Phase 3 · 46 location(s) · Alkermes, Inc. · NCT06767683Extended-release Sodium Oxybate in Children
Phase 2 · 1 location(s) · Stanford University · NCT06809803A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1
Phase 3 · 10 location(s) · Alkermes, Inc. · NCT07540897A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
NA · 1 location(s) · University of Sydney · NCT07006233A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Phase 2/Phase 3 · 52 location(s) · Takeda · NCT05816382Mentalizating in Adults Suffering from Narcolepsy Type 1.
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT06336057Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
NA · 1 location(s) · Hospices Civils de Lyon · NCT06457945Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2 · 37 location(s) · Centessa Pharmaceuticals (UK) Limited · NCT06752668A Phase 1, First-in-human Study of VX-433
Phase 1 · 1 location(s) · Vertex Pharmaceuticals Incorporated · NCT07584434Decreasing Nightmares in Adults With Narcolepsy
NA · 1 location(s) · University of Utah · NCT06383806Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
Phase N/A · 10 location(s) · Takeda · NCT07299097A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
Phase 2/Phase 3 · 1 location(s) · Takeda · NCT07646678Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
Phase N/A · 2 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT06292598A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · 25 location(s) · Takeda · NCT07363720
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.